BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25549213)

  • 1. Involvement of the Ca²⁺ signaling pathway in osteoprotegerin inhibition of osteoclast differentiation and maturation.
    Fu Y; Gu J; Wang Y; Yuan Y; Liu X; Bian J; Liu ZP
    J Vet Sci; 2015; 16(2):151-6. PubMed ID: 25549213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin influences the bone resorption activity of osteoclasts.
    Fu YX; Gu JH; Zhang YR; Tong XS; Zhao HY; Yuan Y; Liu XZ; Bian JC; Liu ZP
    Int J Mol Med; 2013 Jun; 31(6):1411-7. PubMed ID: 23563320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin induces podosome disassembly in osteoclasts through calcium, ERK, and p38 MAPK signaling pathways.
    Zhao H; Liu X; Zou H; Dai N; Yao L; Gao Q; Liu W; Gu J; Yuan Y; Bian J; Liu Z
    Cytokine; 2015 Feb; 71(2):199-206. PubMed ID: 25461399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
    Karst M; Gorny G; Galvin RJ; Oursler MJ
    J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of osteoprotegerin on osteoclast formation and function under serum-free conditions.
    Fu YX; Gu JH; Zhang YR; Tong XS; Zhao HY; Yuan Y; Liu XZ; Bian JC; Liu ZP
    J Vet Sci; 2013; 14(4):405-12. PubMed ID: 23820214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the mitogen‑activated protein kinase signaling pathway in osteoprotegerin‑induced inhibition of osteoclast differentiation and maturation.
    Fu Y; Gu J; Wang Y; Yuan Y; Liu X; Bian J; Liu Z
    Mol Med Rep; 2015 Nov; 12(5):6939-45. PubMed ID: 26329402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
    Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
    BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiosteoclastic bone resorption activity of osteoprotegerin via enhanced AKT/mTOR/ULK1-mediated autophagic pathway.
    Zhao H; Sun Z; Ma Y; Song R; Yuan Y; Bian J; Gu J; Liu Z
    J Cell Physiol; 2020 Mar; 235(3):3002-3012. PubMed ID: 31535378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity.
    Li B; Lu D; Chen Y; Zhao M; Zuo L
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RhoV mediates apoptosis of RAW264.7 macrophages caused by osteoclast differentiation.
    Song R; Liu X; Zhu J; Gao Q; Wang Q; Zhang J; Wang D; Cheng L; Hu D; Yuan Y; Gu J; Liu Z
    Mol Med Rep; 2015 Feb; 11(2):1153-9. PubMed ID: 25354898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
    Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
    J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
    Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.